References
1. Nauck M.A., Wefers J., Meier J.J. Treatment of type 2 diabetes: challenges, hopes, and anticipated successes. Lancet Diabetes Endocrinol. 2021; 9 (8): 525–44.
2. Deacon C.F. Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes. Front Endocrinol (Lausanne). 2019; 10: 80. DOI: https://doi.org/10.3389/fendo.2019.00080
3. Saini K., Sharma S., Khan Y. DPP-4 inhibitors for treating T2DM-hype or hope? an analysis based on the current literature. Front Mol Biosci. 2023; 10: 1130625.
4. Hattori S. Ten-year follow-up of sitagliptin treatment in patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2021; 13: 1–7.
5. Rizzo M.R., Barbieri M., Fava I., Desiderio M., Coppola C., Marfella R., et al. Sarcopenia in elderly diabetic patients: role of dipeptidyl peptidase 4 inhibitors. J Am Med Dir Assoc. 2016; 17 (10): 896–901.
6. Green J.B., Bethel M.A., Armstrong P.W., Buse J.B., Engel S.S., Garg J., et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015; 373 (3): 232–42.
7. Scirica B.M., Braunwald E., Raz I., Cavender M.A., Morrow D.A., Jarolim P., et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014; 130 (18): 1579–88.
8. Rosenstock J., Perkovic V., Johansen O.E., Cooper M.E., Kahn S.E., Marx N., et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019; 321 (1): 69–79.
9. Rosenstock J., Kahn S.E., Johansen O.E., Zinman B., Espeland M.A., Woerle H.J., et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA. 2019; 322 (12): 1155–66.
10. Zannad F., Cannon C.P., Cushman W.C., Bakris G.L., Menon V., Perez A.T., et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015; 385 (9982): 2067–76.
11. Liu J., Li L., Deng K., Xu C., Busse J.W., Vandvik P.O., et al. Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis. BMJ. 2017; 357: j2499.
12. Hu P., Yin Q., Deckert F., Jiang J., Liu D., Kjems L., et al. Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers. J Clin Pharmacol. 2009; 49 (1): 39–49.
13. Balas B., Baig M.R., Watson C., Dunning B.E., Ligueros-Saylan M., Wang Y., et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab. 2007; 92 (4): 1249–55.
14. Mari A., Scherbaum W.A., Nilsson P.M., Lalanne G., Schweizer A., Dunning B.E., et al. Characterization of the influence of vildagliptin on model-assessed β-cell function in patients with type 2 diabetes and mild hyperglycemia. J Clin Endocrinol Metab. 2008; 93 (1): 103–9.
15. Scherbaum W.A., Schweizer A., Mari A., Nilsson P.M., Lalanne G., Wang Y., et al. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2‐year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab. 2008; 10 (11): 1114–24.
16. Das S., Gupta A.K., Bandyopadhyaya B., Darla B.H., Arya V., Abhyankar M., et al. Data on vildagliptin and vildagliptin plus metformin combination in type-2 diabetes mellitus management. Bioinformation. 2021; 17 (3): 413–23.
17. Matthews D.R., Paldánius P.M., Proot P., Chiang Y., Stumvoll M, Del Prato S.; VERIFY Study Group. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019; 394 (10 208): 1519–29.
18. McInnes G., Evans M., Del Prato S., Stumvoll M., Schweizer A., Lukashevich V., et al. Cardiovascular and heart failure safety profile of vildagliptin: a meta‐analysis of 17 000 patients. Diabetes Obes Metab. 2015; 17 (11): 1085–92.
19. Bekiari E., Rizava C., Athanasiadou E., Papatheodorou K., Liakos A., Karagiannis T., et al. Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes. Endocrine. 2016; 52 (3): 458–80.
20. McMurray J.J.V., Ponikowski P., Bolli G.B., Lukashevich V., Kozlovski P., Kothny W., et al. Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial. JACC Heart Fail. 2018; 6 (1): 8–17.